HCM
PTCT icon

Highbridge Capital Management’s PTC Therapeutics PTCT Stock Holding History

Highbridge Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-310,300
Closed -$10.1M – 1755
2015
Q4 		$10.1M Buy
310,300
+10,100
+3% +$297K 0.15% 170
2015
Q3 		$8.02M Buy
+300,200
New +$12.8M 0.12% 214

Other funds holding PTCT

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Highbridge Capital Management's PTCT Position: Q4 2016 in Review

Highbridge Capital Management sold out of PTC Therapeutics (PTCT) in Q4 2016, closing a stake of 27,239 shares — an estimated $382K sold.

Highbridge Capital Management first reported a position in PTCT in Q4 2014 and held it in 6 quarters. The position peaked at $20.5M in Q2 2015. 123 funds tracked by Wall St. Rank hold PTCT as of Q4 2016.

  • Highbridge Capital Management reported no remaining PTC Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 27,239 PTC Therapeutics shares in Q4 2016, an estimated $382K.
  • Highbridge Capital Management first reported a position in PTC Therapeutics in Q4 2014 and held it in 6 quarters.
  • Highbridge Capital Management's PTC Therapeutics position peaked at $20.5M in Q2 2015.
  • 123 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.